Development of hepatorenal syndrome in bile duct ligated rats

World Journal of Gastroenterology

Volumn 14, Issue 28, 2008, Pages 4505-4511

  Pereira, Regina M ^a   dos Santos, Robson A S ^b   Oliveira, Eduardo A ^b   Leite, Virginia H R ^b   Dias, Filipi L C ^b   Rezende, Alysson S ^b   Costa, Lincoln P ^b   Barcelos, Lucíola S ^b   Teixeira, Mauro M ^b   Silva, Ana Cristina Simões ^b  

^a CENTRO UNIVERSITÁRIO DE BELO HORIZONTE   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bile duct ligation; Hepatorenal syndrome; Renal function; Renin angiotensin system

Indexed keywords

CREATININE; HYDROXYPROLINE; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; FREE WATER CLEARANCE; HEPATORENAL SYNDROME; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; LIVER FIBROSIS; LIVER PARENCHYMA; MALE; NONHUMAN; PATHOPHYSIOLOGY; RAT; SODIUM URINE LEVEL; URINE OSMOLALITY; WISTAR RAT;

EID: 58149104118     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4505     Document Type: Article

References (33)

1. Bataller R, Sort P, Gines P, Arroyo V. Hepatorenal syndrome: definition, pathophysiology, clinical features and management. Kidney Int Suppl 1998; 66: S47-S53
2. Cardenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006; 10: 371-385, ix-x
3. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-170
4. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002; 34: 592-605
5. Oberti F, Vuillemin E, Fort J, Cales P. [Experimental models of portal hypertension] Gastroenterol Clin Biol 2000; 24: 896-901
6. Poo JL, Estanes A, Pedraza-Chaverri J, Cruz C, Perez C, Huberman A, Uribe M. [Chronology of portal hypertension, decreased sodium excretion, and activation of the renin-angiotensin system in experimental biliary cirrhosis] Rev Invest Clin 1997; 49: 15-23
7. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-311
8. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-229
9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
10. Cardenas A, Gines P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 338-348
11. Jonassen TE, Brond L, Torp M, Graebe M, Nielsen S, Skott O, Marcussen N, Christensen S. Effects of renal denervation on tubular sodium handling in rats with CBL-induced liver cirrhosis. Am J Physiol Renal Physiol 2003; 284: F555-F563
12. Alon U, Berant M, Mordechovitz D, Better OS. The effect of intrarenal infusion of bile on kidney function in the dog. Clin Sci (Lond) 1982; 62: 431-433
13. Israeli BA, Bogin E. Biochemical changes in liver, kidney and blood associated with common bile duct ligation. Clin Chim Acta 1986; 160: 211-221
14. Ozdogan O, Goren M, Ratip S, Giral A, Moini H, Enc F, Birsel S, Berkman K, Tozun N. Role of endothelin-1 in a cirrhotic rat model with endotoxin induced acute renal failure. Hepatol Res 2002; 24: 114
15. Aliaga L, Zozoya JM, Omar M, Mediavilla JD, Prieto J. Interrelationships between systemic hemodynamics, urinary sodium excretion, and renin-angiotensin system in cirrhosis. Acta Gastroenterol Belg 1995; 58: 213-221
16. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89: 221-231
17. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34
18. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol 2004; 143: 117-130
19. Souza Dos Santos RA, Passaglio KT, Pesquero JB, Bader M, Simoes E Silva AC. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 2001; 38: 660-664
20. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB, Simoes e Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 2007; 46: 674-681
21. Simoes e Silva AC, Pinheiro SV, Pereira RM, Ferreira AJ, Santos RA. The therapeutic potential of Angiotensin-(1-7) as a novel Renin-Angiotensin System mediator. Mini Rev Med Chem 2006; 6: 603-609
22. Chappell MC, Modrall JG, Diz DI, Ferrario CM. Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 2004; 143: 77-89
23. Santos RA, Simoes e Silva AC, Magaldi AJ, Khosla MC, Cesar KR, Passaglio KT, Baracho NC. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 1996; 27: 875-884
24. Garcia NH, Garvin JL. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 1994; 5: 1133-1138
25. Vallon V, Richter K, Heyne N, Osswald H. Effect of intratubular application of angiotensin 1-7 on nephron function. Kidney Blood Press Res 1997; 20: 233-239
26. Magaldi AJ, Cesar KR, de Araujo M, Simoes e Silva AC, Santos RA. Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch 2003; 447: 223-230
27. Andreatta-van Leyen S, Romero MF, Khosla MC, Douglas JG. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). Kidney Int 1993; 44: 932-936
28. Handa RK. Angiotensin-(1-7) can interact with the rat proximal tubule AT(4) receptor system. Am J Physiol 1999; 277: F75-F83
29. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 2002; 39: 799-802
30. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 2003; 284: H1985-H1994
31. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005; 54: 1790-1796
32. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW. Upregulation of hepatic angiotensin-,converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007; 47: 387-395
33. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263